First clinical studies with Orlistat: A short review

被引：69

作者：

Drent, ML ^{[1
]}

vanderVeen, EA ^{[1
]}

机构：

[1] FREE UNIV AMSTERDAM HOSP,DEPT ENDOCRINOL,1081 HV AMSTERDAM,NETHERLANDS

来源：

OBESITY RESEARCH | 1995年 / 3卷

关键词：

lipase inhibition; Orlistat; human obesity; hormonal systems;

D O I：

10.1002/j.1550-8528.1995.tb00236.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Lipase inhibition, leading to decreased intestinal fat adbsorption can be used in the treatment of obesity, Orlistat, a lipase inhibitor, in a dose of 50 mg three times a day leads to a significant increase in weight loss compared to placebo in moderately obese people, These results are confirmed in a multiple-dose study using 10 mg,60 mg and 120 mg Orlistat three times a day vs, placebo, The use of lipase inhibition has no significant influence on fasting levels of several hormonal systems,including thyroid hormones, catecholamines and IGF-I, The same is true for the responses of several gastrointestinal and pancreatic hormones after a liquid high-fat mixed meal, In general, Orlistat is tolerated very well, although a higher occurence of gastrointestinal side effects is seen.

引用

页码：S623 / S625

页数：3